Followers | 220 |
Posts | 13482 |
Boards Moderated | 3 |
Alias Born | 06/20/2022 |

Monday, November 18, 2024 12:28:49 PM

Volume: | 197,626 |
Day Range: | 0.2178 - 0.245 |
Bid: | 0.2227 |
Ask: | 0.23 |
Last Trade Time: | 7:59:04 PM EDT |
Total Trades: | 2,856 |
Recent HCWB News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2025 08:40:08 PM
- HCW Biologics Announces 1-for-40 Reverse Stock Split • GlobeNewswire Inc. • 04/01/2025 08:35:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2025 08:30:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/28/2025 07:45:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 07:40:07 PM
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/28/2025 07:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2025 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 12:00:08 PM
- HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements • GlobeNewswire Inc. • 03/06/2025 11:55:18 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/21/2025 10:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2025 10:25:09 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/11/2025 09:54:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2025 09:45:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2025 12:30:08 PM
- HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial • GlobeNewswire Inc. • 02/03/2025 12:15:07 PM
- HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 • GlobeNewswire Inc. • 01/15/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 01:30:10 PM
- HCW Biologics Inc. Received NASDAQ Staff Determination Letter • GlobeNewswire Inc. • 12/23/2024 01:10:13 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 12/05/2024 09:37:20 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/22/2024 09:53:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:45:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2024 09:42:31 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 11/20/2024 05:54:40 PM
- HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules • GlobeNewswire Inc. • 11/19/2024 02:27:48 AM
- HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate • GlobeNewswire Inc. • 11/18/2024 12:00:27 PM
Wytec Prepares for 1st AI Gunshot Detection Pilot • WYTC • Apr 4, 2025 7:09 AM
ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors • CNTM • Apr 2, 2025 9:00 AM
Nightfood Holdings Completes Acquisition of Carryout Supplies, Deepening Vertical Integration in AI-Powered Hospitality Automation • NGTF • Apr 2, 2025 8:30 AM
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City • AVAI • Apr 2, 2025 8:00 AM
Glidelogic Corp. Unveils ResearchMind - Pioneering AI-Driven Research Innovation for a Global Academic Community • GDLG • Apr 1, 2025 2:10 PM
Fifty 1 Labs, Inc. Celebrates Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary Genetic Networks • FITY • Apr 1, 2025 9:30 AM